The Journal of Neuroscience, November 21, 2007, 27(47):12884-12892; doi:10.1523/JNEUROSCI.4101-07.2007
Previous Article | Next Article 
Neurobiology of Disease
Characterization of the Kynurenine Pathway in Human Neurons
Gilles J. Guillemin,1,4
Karen M. Cullen,3
Chai K. Lim,4
George A. Smythe,2
Brett Garner,6
Vimal Kapoor,7
Osamu Takikawa,8 and
Bruce J. Brew4,5
1Department of Pharmacology, School of Medical Sciences, and 2Biomedical Mass Spectrometry Facility, University of New South Wales, Sydney 2052, Australia, 3Anatomy and Histology, School of Medical Science and the Bosch Institute, The University of Sydney, New South Wales 2006, Australia, 4Centre for Immunology and 5Departments of Neurology and HIV Medicine, St. Vincent's Hospital, Sydney 2010, Australia, 6Prince of Wales Medical Research Institute, Randwick 2031, New South Wales, Australia, 7Department of Medicine and Pharmacology, The University of Western Australia, Crawley 6009, Australia, and 8Laboratory of Radiation Safety, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Gengo, Morioka, Obu 474-8511, Japan
Correspondence should be addressed to Dr. Gilles J. Guillemin, University of New South Wales, Wallace Wurth Building, Room 309, Sydney, NSW 2052, Australia. Email: g.guillemin{at}cfi.unsw.edu.au
The kynurenine pathway is a major route of L-tryptophan catabolism producing neuroactive metabolites implicated in neurodegeneration and immune tolerance. We characterized the kynurenine pathway in human neurons and the human SK-N-SH neuroblastoma cell line and found that the kynurenine pathway enzymes were variably expressed. Picolinic carboxylase was expressed only in primary and some adult neurons but not in SK-N-SH cells. Because of this difference, SK-N-SH cells were able to produce the excitotoxin quinolinic acid, whereas human neurons produced the neuroprotectant picolinic acid. The net result of kynurenine pathway induction in human neurons is therefore predicted to result in neuroprotection, immune regulation, and tumor inhibition, whereas in SK-N-SH cells, it may result in neurotoxicity, immune tolerance, and tumor promotion. This study represents the first comprehensive characterization of the kynurenine pathway in neurons and the first description of the involvement of the kynurenine pathway as a mechanism for controlling both tumor cell neurotoxicity and persistence.
Key words: human neurons; neuroblastoma; kynurenine pathway; indoleamine 2,3-dioxygenase; picolinic acid; quinolinic acid; neurotoxicity; tumor tolerance
Received April 17, 2007;
accepted Oct. 8, 2007.
Correspondence should be addressed to Dr. Gilles J. Guillemin, University of New South Wales, Wallace Wurth Building, Room 309, Sydney, NSW 2052, Australia. Email: g.guillemin{at}cfi.unsw.edu.au
This article has been cited by other articles:

|
 |

|
 |
 
I. T. Whiteman, O. L. Gervasio, K. M. Cullen, G. J. Guillemin, E. V. Jeong, P. K. Witting, S. T. Antao, L. S. Minamide, J. R. Bamburg, and C. Goldsbury
Activated Actin-Depolymerizing Factor/Cofilin Sequesters Phosphorylated Microtubule-Associated Protein during the Assembly of Alzheimer-Like Neuritic Cytoskeletal Striations
J. Neurosci.,
October 14, 2009;
29(41):
12994 - 13005.
[Abstract]
[Full Text]
[PDF]
|
 |
|